Royal Bank Of Canada Lowers BioCryst Pharmaceuticals (NASDAQ:BCRX) Price Target to $13.00

BioCryst Pharmaceuticals (NASDAQ:BCRX) had its price objective decreased by equities researchers at Royal Bank Of Canada from $14.00 to $13.00 in a research note issued on Thursday,Benzinga reports. The firm presently has an “outperform” rating on the biotechnology company’s stock. Royal Bank Of Canada’s target price suggests a potential upside of 38.59% from the company’s current price.

BCRX has been the subject of a number of other research reports. Weiss Ratings reissued a “hold (c)” rating on shares of BioCryst Pharmaceuticals in a report on Monday, June 1st. Citizens Jmp boosted their price target on BioCryst Pharmaceuticals from $25.00 to $28.00 and gave the stock a “market outperform” rating in a research report on Thursday, May 7th. HC Wainwright reissued a “buy” rating and issued a $32.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Tuesday, June 30th. Cantor Fitzgerald raised their price objective on BioCryst Pharmaceuticals from $27.00 to $29.00 and gave the company an “overweight” rating in a report on Tuesday, June 30th. Finally, Needham & Company LLC decreased their price objective on BioCryst Pharmaceuticals from $18.00 to $16.00 and set a “buy” rating on the stock in a report on Wednesday, May 6th. Eight investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, BioCryst Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $20.60.

BioCryst Pharmaceuticals Stock Up 0.9%

Shares of NASDAQ BCRX opened at $9.38 on Thursday. The firm has a market cap of $2.38 billion, a price-to-earnings ratio of -6.25 and a beta of 0.55. The company’s 50-day simple moving average is $9.33 and its 200-day simple moving average is $8.71. BioCryst Pharmaceuticals has a 52-week low of $6.00 and a 52-week high of $11.22.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $0.30 earnings per share for the quarter, beating analysts’ consensus estimates of $0.15 by $0.15. BioCryst Pharmaceuticals had a negative net margin of 40.90% and a negative return on equity of 86.89%. The firm had revenue of $218.25 million for the quarter, compared to analyst estimates of $183.28 million. During the same period last year, the company posted $0.15 EPS. BioCryst Pharmaceuticals’s quarterly revenue was up 33.6% compared to the same quarter last year. Equities research analysts anticipate that BioCryst Pharmaceuticals will post -2.52 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. BlackRock Inc. purchased a new stake in shares of BioCryst Pharmaceuticals in the second quarter valued at approximately $238,930,000. Vanguard Group Inc. increased its holdings in shares of BioCryst Pharmaceuticals by 2.2% in the fourth quarter. Vanguard Group Inc. now owns 22,273,375 shares of the biotechnology company’s stock valued at $173,732,000 after purchasing an additional 482,494 shares during the last quarter. RA Capital Management L.P. purchased a new position in BioCryst Pharmaceuticals during the fourth quarter worth approximately $123,452,000. Deerfield Management Company L.P. lifted its position in BioCryst Pharmaceuticals by 159.4% during the third quarter. Deerfield Management Company L.P. now owns 12,169,000 shares of the biotechnology company’s stock worth $92,363,000 after buying an additional 7,477,000 shares in the last quarter. Finally, State Street Corp boosted its stake in BioCryst Pharmaceuticals by 12.9% during the fourth quarter. State Street Corp now owns 11,073,211 shares of the biotechnology company’s stock worth $86,371,000 after buying an additional 1,265,773 shares during the last quarter. 85.88% of the stock is currently owned by institutional investors and hedge funds.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.